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compared RAB25 DNA copy number aberrations (CNAs) and expression level in lu-
minal B tumors with those observed in breast cancers of the other molecular subtypes.
Methods: To further define molecular alterations associated with the luminal B subtype
we studied, with high-Troughput molecular analysis (CGHarray), copy number aber-
rations and RAB25 gene expression (DNAmicroarray) deregulation in primary breast
cancer samples.
Results: RAB25 gene is not targeted by genomic alterations in a high proportion of
breast cancers. RAB25mRNA expression and RAB 25 protein level was deregulated in
breast cancers. Comparison with clinical features between breast tumors with and with-
out RAB 25 deregulation showed that RAB25 high expression was associated with the
expression of estrogen receptor (ER), high expression of Ki67 proliferative index and
luminal B breast cancer molecular subtypes.
Conclusions: we have identified RAB25mRNA and protein expression deregulated in
luminal B breast cancer molecular subtype suggesting RAB25 as a potential therapeutic
target in this aggressive subtype and for which no targeted therapy exists at yet. A better
understanding of the involvement of RAB25 in luminal B breast cancer might explain
the role in the development and/or hormone resistance of this aggressive subtype.
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Background:Ovarian cancer is associated with the highest mortality rate among gynae-
cologic malignancies. There is a need to refine classification of ovarian cancer and iden-
tify novel targets. The mammalian target of rapamycin (mTOR) pathway has a crucial
role in the regulation of translation of specific proteins associated with ovarian cancer
progression. Themajor downstream effectors of mTOR are eukaryotic initiation factor
4E-binding protein 1 (4EBP1) and ribosomal protein S6 kinase (p70S6K).We aimed to
investigate the biological significance of this pathway in ovarian cancer.
Methods: Investigation of mTORC1, 4EBP1 and p70S6K protein expression, was car-
ried out on tissue microarrays of 195 consecutive ovarian epithelial cancers treated at
NottinghamUniversity Hospitals (NUH) between 2000 and 2007. Clinicopathological
and outcome data were collected.
Results:High cytoplasmic expression of both 4EBP1 and p70S6K was associated with
serous type carcinoma (p¼ 0.005 and p¼ 0.02 respectively). High expression of 4EBP1
was seenmore frequently in cases treated with early debulking (p¼ 0.005). Univariate
outcome analysis showed an inverse association between 4EBP1 expression and overall
survival (p¼ 0.005) and development of local recurrence (p¼ 0.005). P70S6K showed
inverse association with local recurrence (p¼ 0.002). High cytoplasmic expression of
mTORC1 was inversely associated local recurrence (p¼ 0.032) and borderline signifi-
cance with poor overall survival (p¼ 0.079).
Conclusions:mTORC1 and its downstream effectors, 4EBP1 and p70S6K positive ex-
pression predicts local recurrence and poor survival in ovarian cancer patients.
Therefore, this could be targeted as a potential pathway that could improve patients’
survival and reduce tumour recurrence.
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Background: Telomeres play a vital role in maintaining the integrity of the genome.
Mammalian telomeres are certainly transcribed into telomeric repeat-containing
RNA (TERRA). This Long non-coding RNA participates in the regulation of telomere
length and telomerase activity. As reported, lncRNAs play important roles in gastric
cancer progression. Telomerase and its major catalytic subunit (hTERT) are upregu-
lated in most cancers, including gastric cancer. RNA interference (RNAi) has been
proven to be a powerful tool for gene knockdown and hold good promise for the treat-
ment of human diseases including cancer. In this study, we investigated the effect of
hTERT repression on the TERRA expression and telomere length in multiple
passages.
Methods: AGS gastric cancer cell line was treated with hTERT FlexiTube siRNA and
Hiperfect transfection reagent. Cell viability was examined byMTT assay. A DAPI
staining method was used to analysis cell cycle by Flow Cytometry. Real-time PCR was
used to evaluate the expression level of hTERT and TERRA and assessment of telomere
length.
Results: TheMTT assay showed that increasing the exposure time to 48 hours
decreased cell viability below the 50% viability mark. The flow cytometry cell cycle
analysis showed a significant increasing in the number of cells in G1 phase and decreas-
ing in the number of cells in S phase. The results of the qRT-PCR analysis demonstrated
that siRNA transfection decreased the hTERT expression, although has no significant
effect on TERRA expression in early passages. However, upregulation of TERRA ex-
pression in the passage of 20 compared to the control cells has been shown. Also, telo-
mere length measurement in each passage was decreased after hTERT siRNA
treatment.
Conclusions: The significant downregulation of hTERTmRNA inhibited the cell via-
bility of AGS cells and cell cycle arrest. This study provides the fact that downregulation
of hTERT expression had no effect on TERRA expression level in early passages of AGS
cell line. Also, showed a direct link between decreasing in telomere length and downre-
gulation of hTERT expression.
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Background: Telomerase is in charge of telomere extending and is triggered in around
90% of cancers. hTERT is the controlling subunit of telomerase and plays a critical role
in the activation of telomerase. The mechanism through which hTERT regulate the
invasion andmetastasis of cancer is unclear. miRNAs can regulate the expression of
hTERT. It was previously reported that miR-1266 can target hTERT in gastric cancer.
In this study, we have made the first report of miR-1266-5p role on the hTERT expres-
sion, telomerase activity, and biological functions, including cell proliferation and cell
cycle in AGS, MCF7, A375, and HepG2 cell lines.
Methods: AGS, MCF7, A375, and HepG2 cell lines were transfected with miR-1266-5p
mimic and inhibitor reagents. The Expression levels of miR-1266-5p, hTERT, and
transfection efficiency were analyzed by Taqman qRT-PCR. The cell proliferation and
cell cycle changes were detected byMTT Calorimetric Assay and flow cytometry,
respectively. Also, Quantitative TRAP Assay was used to detect telomerase activity.
Results: The expression of miR-1266-5p significantly was increased after transfection
bymimic compared to control cells. While its expression was decreased by the inhibi-
tor. Upregulated miR-1266-5p significantly decreased cell growth, although inhibitor
promoted cell proliferation. This finding was confirmed by cell cycle analysis, as upre-
gulation of miR-1266-5p induced cells cycle arrest at the transition of G1 to S phase
and led to G0/G1 entry, while the downregulation of miR-1266-5p promoted cell
growth and led to G2/M entry. Concordantly, the overexpression of miR-1266-5p
resulted in down-regulated hTERT expression and also suppressed telomerase activity.
Conclusions: Taken together, the findings showed that miR-1266-5p acts as hTERT
and telomerase activity suppressor. miR-1266-5p could also decrease cell proliferation
and induce cell cycle arrest, while its inhibitor eliminates miR-1266-5p effects. Thus,
upregulation of miR-1266-5pmay be considered as a novel therapeutic target in
cancer.
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Background: The regulation of microRNA (miRNA) biogenesis, function and degrad-
ation is regulated by a range of mechanisms involving RNA-binding-proteins and pro-
tein-RNA interactions. The potential contribution of regulatory miRNAs to the
expression of these RNA interactor proteins that could control other miRNAs expres-
sion is still unclear.
Methods:Here, we demonstrate a circuit of miRNAs regulation between onco-
genic and tumor suppressor miRNAs in a chemotherapy-resistant ovarian cancer
model.
Results:We identified and characterized miR-25-3p andmiR-15a-5p as negative
regulators of RNA-binding protein hnRNPA1 expression that is required for the pro-
cessing of miR-18a-3p, an inhibitor of the K-RAS oncogene. The inhibition of miR-
25-3p andmiR-15a-5p decreased the proliferation, motility, invasiveness and angio-
genesis potential and also increases apoptosis when combined with docetaxel.
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